Mark Peterson

A small cybersecurity firm just gained access to Florida's $90M consulting budget. Is this a game-changing opportunity or a high-stakes bet for Cycurion?

Zevra Therapeutics adds M&A expert Alicia Secor to its board, a move signaling a sharpened focus on commercial growth and strategic transactions.

CTW Cayman is bypassing app stores with HTML5 games. Its new Crayon Shinchan title reveals a disruptive strategy leveraging anime IP for global dominance.

A tiny mouse's song reveals a new path for evolution and technology. CSHL's research could disrupt everything from AI to treatments for speech disorders.

With EU approval for its novel acne drug Winlevi, Glenmark makes a strategic pivot, challenging dermatology incumbents and testing its European ambitions.

With positive data, safety board approval, and elite site expansion, Clearmind Medicine is making strategic moves to disrupt the $249B Alcohol Use Disorder market.

A new AI collaboration between Amazon and Trane Technologies is slashing energy use in fulfillment centers, setting a new standard for sustainable logistics.

Intercont Cayman's new partnership promises green revenue from the EV boom, but a closer look reveals a high-risk strategy and a mysterious corporate vision.

Hadron Energy unveils an all-star board for its $1.2B public listing, betting its micro-nuclear reactors can solve the AI industry's energy crisis.

Facing financial headwinds, Treasure Global projects explosive growth through a high-stakes pivot into fintech. Can this strategic gamble pay off?

A new antisense therapy, zorevunersen, shows disease-modifying potential, shifting focus from seizure control to tackling the genetic root of the disease.

A renewable energy company's leap into mining raises questions. Is it brilliant vertical integration or a high-risk gamble diluting its green mission?

Bicara Therapeutics' latest data for its dual-action antibody shows impressive consistency, de-risking its pivotal trial for a tough head and neck cancer.

With copper prices soaring, Amerigo renews its share buyback, doubling down on a shareholder-first strategy built on zero debt and market confidence.

Faraday Future's bold five-year plan targets 500,000 EVs, but with a history of delays and a critical need for cash, can it deliver or is it a dream?

With cash dwindling and a key trial missing its mark, IO Biotech faces a critical test at two investor conferences. Can it salvage its lead drug?

Adial Pharmaceuticals secures a crucial $2.86M, but the deal's structure raises serious questions about shareholder dilution versus fueling its promising AD04 drug.

TeraGo partners with cybersecurity giant Fortinet, a strategic move to challenge incumbents by bundling secure networking with its unique wireless assets.

After fatal safety events restricted its blockbuster Duchenne therapy, Sarepta is launching a pivotal new study. Can it reclaim a critical market?

New survival data for Inluriyo, precision insights for Verzenio, and a next-gen drug signal Lilly's aggressive strategy to dominate HR+ breast cancer.